Trevena Reports First Quarter 2019 Results
May 10, 2019 07:00 ET
|
Trevena Inc.
— Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to host conference call...
Trevena Reports Fourth Quarter and Full Year 2018 Results
March 13, 2019 07:00 ET
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
March 11, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...
Trevena Announces $10 Million Registered Direct Offering of Common Stock
January 30, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
January 28, 2019 07:00 ET
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
Trevena Announces Presentations During the 36th Annual Scientific Meeting of the American Pain Society
May 17, 2017 07:00 ET
|
Trevena Inc.
– Results presented from the successful APOLLO-1 Phase 3 pivotal efficacy study of OLINVOTM (oliceridine injection) in moderate-to-severe acute pain – – New preclinical research highlights the...